Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeEAM vs CEM Conditioning in Lymphoma
NCT05813132Completed
- Sponsor
- Rehab Werida
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bendamustine in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Rehab Werida. Primary endpoint: Incidence of Side Effects at 3 months. Started Nov 2022; status: completed.
02
Drugs
bendamustine
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05813132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813132.